- Adding anlotinib in gradual or local progression on first-line EGFR-TKIs for advanced non-small cell lung cancer: A single-arm, multicenter, phase II trialChen, H.; Hu, Y.; Fan, Y.; Wu, G.; Cang, S.; Yang, Y.; Yang, N.; Ma, R.; Jing, G.; Liu, A.; Xu, X.; Tang, S.; Cheng, Y.; Yu, Y.; Wu, Y-L.
- A multicenter, randomized, double-blind, phase III study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER)Zhang, L.; Fang, W.; Yu, Q.; Zhang, H.; Wu, G.; Wu, D.; Lin, Y.; Zhu, J.; Chen, J.; Hu, X.; Lan, B.; Zhou, Z.; Lin, H.; Wang, Z.; Lei, X.; Pan, S.; Chen, L.; Zhang, J.; Kong, T.; Yu, H.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
- Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC): Initial results from a registrational phase II studyZhou, Q.; Meng, X.; Sun, L.; Huang, D.; Yang, N.; Yu, Y.; Zhao, M.; Zhuang, W.; Hu, Y.; Pan, Y.; Sun, M.; Shan, J.; Guo, R-H.; Chu, Q.; Xu, C.; Lin, J.; Huang, J.; Huang, M.; Shen, Y.; Wu, Y-L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
会议论文
Efficacy of anlotinib in posterior line treatment of locally advanced and metastatic NSCLC with KRAS mutation
6阅读
